...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Additional Exempt Distribution- 2023-03-31

NBB - This cannibalization idea has surfaced often but I struggle with it. It seems to me that for this to work for Pharma, they all have to be in collusion on keeping it off of the market. If it hurts profits to bring a product to market that cannibalizes your other products, think of how much more it would hurt if someone else brought it to market and took away from your sales without you recognizing anything from it. Pharma would be safer to buy it and shelf it rather than let someone else attain the science.  

Share
New Message
Please login to post a reply